RxDoctor Payments Data

Robert Macdonald, DO

Family Medicine · Richmond, ILNPI 1679640379

Payments from drug & device makers

$695in general payments, 2019–2025

Across 38 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$158
  • Novo Nordisk$100
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$95
  • AstraZeneca$75
  • Boehringer Ingelheim$64
  • Shire North American Group Inc$44
  • plus $159 from 7 others

What the payments were for

  • Food & beverage$695100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$695 in reported general payments places this provider in the 65th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$89,459
Medicare patients
297
Services billed
1,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$44,265
JardianceEmpagliflozin31$39,535
Tresiba Flextouch U-200Insulin Degludec14$27,268
JanuviaSitagliptin Phosphate22$22,803
FarxigaDapagliflozin Propanediol18$21,407
XareltoRivaroxaban20$20,424
EliquisApixaban35$19,810
MyrbetriqMirabegron36$18,188
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$13,036
Novolog FlexpenInsulin Aspart21$10,097
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,438
Doxepin Hcl15$3,016
SynthroidLevothyroxine Sodium32$2,919
Atorvastatin Calcium403$2,824
Levothyroxine Sodium202$2,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$100$44,26526 claims
Boehringer IngelheimJardiance$64$39,53531 claims
MerckJanuvia$33$22,80322 claims
AstraZenecaFarxiga$75$21,40718 claims
Astellas Pharma US IncMyrbetriq$15$18,18836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Richmond

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →